INT2650

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1979
Last Reported 2010
Negated 3
Speculated 0
Reported most in Abstract
Documents 50
Total Number 52
Disease Relevance 2.95
Pain Relevance 27.52

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Slc3a1) plasma membrane (Slc3a1) carbohydrate metabolic process (Slc3a1)
Anatomy Link Frequency
neurons 8
brain 4
PFC 3
whisker 2
anterior 1
Slc3a1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Dopamine 2042 100.00 Very High Very High Very High
agonist 425 100.00 Very High Very High Very High
Enkephalin 73 99.98 Very High Very High Very High
dopamine receptor 468 99.96 Very High Very High Very High
Opioid 18 99.90 Very High Very High Very High
Nucleus accumbens 16 99.90 Very High Very High Very High
gABA 386 99.68 Very High Very High Very High
midbrain 55 99.46 Very High Very High Very High
Morphine 14 99.40 Very High Very High Very High
MU agonist 6 99.40 Very High Very High Very High
Disease Link Frequency Relevance Heat
Catalepsy 32 100.00 Very High Very High Very High
Targeted Disruption 45 99.96 Very High Very High Very High
Parkinson's Disease 316 99.44 Very High Very High Very High
Bordatella Infection 3 98.52 Very High Very High Very High
Muscle Rigidity 14 92.64 High High
Congenital Anomalies 32 88.44 High High
Disease 389 85.32 High High
Attention Deficit Hyperactivity Disorder 361 78.52 Quite High
Nociception 2 75.60 Quite High
Respiratory Tract Infection 3 75.04 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Other D2 receptor agonists were tested in the mouse and in the rat vas deferens for their ability to activate D2 and alpha-2 receptors, respectively.
Positive_regulation (activate) of D2 in vas deferens associated with agonist
1) Confidence 0.57 Published 1993 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 7903387 Disease Relevance 0 Pain Relevance 0.86
Since D2 receptor mRNA is generally colocalized with proenkephalin mRNA in striatal neurons, these results demonstrate what is likely a selective cellular increase in proenkephalin mRNA without a parallel increase in D2 mRNA.
Neg (without) Positive_regulation (increase) of D2 mRNA in neurons
2) Confidence 0.56 Published 1994 Journal Exp. Neurol. Section Abstract Doc Link 7867758 Disease Relevance 0 Pain Relevance 0.25
A significant (36%) increase in D2 mRNA was observed in the anterior cingulate cortex.
Positive_regulation (increase) of D2 mRNA in cingulate cortex associated with anterior cingulate cortex
3) Confidence 0.56 Published 1994 Journal Exp. Neurol. Section Abstract Doc Link 7867758 Disease Relevance 0 Pain Relevance 0.33
Thus, increased striatal D2 binding after haloperidol treatment may not be the result of altered D2 gene activity in the striatum or midbrain, but could result from an increase in D2 mRNA in cingulate corticostriatal neurons and/or a longer half-life for the D2 receptor protein in striatal neurons.
Positive_regulation (increase) of D2 mRNA in neurons associated with midbrain
4) Confidence 0.56 Published 1994 Journal Exp. Neurol. Section Abstract Doc Link 7867758 Disease Relevance 0 Pain Relevance 0.37
It may be concluded that D-2 activation induces ejaculation through influence on cholinergic mechanisms and morphine inhibits the ejaculation induced by activation of both cholinergic and dopaminergic systems via opiate receptor sites.
Positive_regulation (activation) of D-2 associated with opiate and morphine
5) Confidence 0.46 Published 1994 Journal Gen. Pharmacol. Section Abstract Doc Link 7958745 Disease Relevance 0 Pain Relevance 0.54
The effect of the peptide is independent of the degree of activation of dopamine D2 receptors which modulate the stimulus-evoked release of [3H]dopamine.
Positive_regulation (activation) of D2 associated with dopamine
6) Confidence 0.41 Published 1989 Journal Brain Res. Section Abstract Doc Link 2550107 Disease Relevance 0 Pain Relevance 0.88
These data indicate that this administration paradigm elevates both preprodynorphin and preproenkephalin mRNAs by a D1-dependent mechanism not requiring D2 activation.
Neg (not) Positive_regulation (activation) of D2
7) Confidence 0.41 Published 1996 Journal Neuroreport Section Abstract Doc Link 8930988 Disease Relevance 0 Pain Relevance 0.79
Thus, increased striatal D2 binding after haloperidol treatment may not be the result of altered D2 gene activity in the striatum or midbrain, but could result from an increase in D2 mRNA in cingulate corticostriatal neurons and/or a longer half-life for the D2 receptor protein in striatal neurons.
Positive_regulation (half-life) of D2 in neurons associated with midbrain
8) Confidence 0.41 Published 1994 Journal Exp. Neurol. Section Abstract Doc Link 7867758 Disease Relevance 0 Pain Relevance 0.36
However, no changes were observed in the amounts of D1, D2, D3 mRNA, or D2 heteronuclear RNA (hnRNA) in the striatum or in the levels of D2 mRNA and hnRNA in the substantia nigra and ventral tegmental area.
Positive_regulation (levels) of D2 mRNA in ventral associated with ventral tegmentum and substantia nigra
9) Confidence 0.41 Published 1994 Journal Exp. Neurol. Section Abstract Doc Link 7867758 Disease Relevance 0 Pain Relevance 0.38
It is concluded that the opioid agonists studied induce a significant elevation in functional D2 sites to the exclusion of D1 sites.
Positive_regulation (elevation) of D2 associated with mu agonist
10) Confidence 0.37 Published 1991 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 1831883 Disease Relevance 0 Pain Relevance 0.85
The mu-agonist sufentanil (1 or 20 micrograms/kg, i.p.), the kappa-agonist U50,488H (10 mg/kg, i.p.) and DADL (1 microgram/animal, i.c.v.) all significantly elevated D2 but not D1 binding site density in rat striatum.
Positive_regulation (elevated) of D2 in striatum associated with agonist and enkephalin
11) Confidence 0.35 Published 1991 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 1831883 Disease Relevance 0 Pain Relevance 0.94
These results indicate that the release of serotonin in the median raphe nucleus does not appear to be regulated by dopaminergic afferents through the activation of dopamine D1 or D2 receptors.
Positive_regulation (activation) of D2 in raphe nucleus associated with dopamine, raphe and serotonin
12) Confidence 0.32 Published 1999 Journal Eur. J. Neurosci. Section Abstract Doc Link 10383619 Disease Relevance 0 Pain Relevance 0.90
These data indicate that the synergistic response to combined D1- and D2-receptor stimulation is mediated by interneuronal interactions involving the activation of D1 and D2 receptors on separate populations of striatal neurons.
Positive_regulation (activation) of D2 in neurons
13) Confidence 0.28 Published 1995 Journal J. Neurosci. Section Abstract Doc Link 8613751 Disease Relevance 0 Pain Relevance 0.79
Dopamine (D2) or gamma-aminobutyric acid (GABAB) receptor activation hyperpolarizes rat melanotrophs and pertussis toxin blocks these responses and the accompanying fall in [Ca2+]i.
Positive_regulation (activation) of D2 in melanotrophs associated with dopamine and bordatella infection
14) Confidence 0.24 Published 1990 Journal Neurosci. Lett. Section Title Doc Link 2163038 Disease Relevance 0.10 Pain Relevance 0.45
We found that D2 agonist-elicited increases in PFC GABA levels were blocked by pretreatment with SR48692, consistent with data indicating that D2 autoreceptor agonists increase neurotensin release from dopamine-neurotensin axons in the PFC.
Positive_regulation (increases) of D2 in PFC associated with dopamine, gaba and agonist
15) Confidence 0.23 Published 2005 Journal J. Neurosci. Section Abstract Doc Link 15716398 Disease Relevance 0.06 Pain Relevance 0.75
Tissues were assayed for D1, D2 and D3 dopamine receptor mRNAs (D1R, D2R and D3R), as well as for mRNAs for tyrosine hydroxylase (TH) and the dopamine transporter (DAT).
Positive_regulation (assayed) of D2 associated with dopamine and dopamine receptor
16) Confidence 0.20 Published 2003 Journal Brain Res. Mol. Brain Res. Section Abstract Doc Link 12654507 Disease Relevance 0 Pain Relevance 0.68
Microdialysis studies showed that activation of D2LRs decreased GABA release in the rat GP while activation of D1LRs increased GABA release (Floran et al., 1990, 1997).
Positive_regulation (activation) of D2LRs associated with gaba
17) Confidence 0.19 Published 2010 Journal Frontiers in Neuroanatomy Section Body Doc Link PMC2987554 Disease Relevance 0 Pain Relevance 0.48
In vitro patch clamp studies in rodent brain slices have suggested that activation of presynaptic D1LRs facilitates glutamate release (Hernandez et al., 2007) while activation of D2LRs reduces it (Hernandez et al., 2006).
Positive_regulation (activation) of D2LRs in brain associated with glutamate
18) Confidence 0.19 Published 2010 Journal Frontiers in Neuroanatomy Section Body Doc Link PMC2987554 Disease Relevance 0 Pain Relevance 0.42
With some exceptions, it appears that activation of D1LRs and D2LRs within the individual nuclei generates similar responses.
Positive_regulation (activation) of D2LRs
19) Confidence 0.19 Published 2010 Journal Frontiers in Neuroanatomy Section Body Doc Link PMC2987554 Disease Relevance 0 Pain Relevance 0.23
We have recently carried out preliminary studies indicating that activation of D1LRs or D2LRs in the monkey STN increases the firing rates of STN neurons, and that D1LR activation decreases bursting activities of these neurons (Rommelfanger et al., 2010).
Positive_regulation (activation) of D2LRs in neurons
20) Confidence 0.19 Published 2010 Journal Frontiers in Neuroanatomy Section Body Doc Link PMC2987554 Disease Relevance 0 Pain Relevance 0.44

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox